Governance Anika Therapeutics, Inc.

ANIK

US0352551081

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
14.20 ^USD	-0.70%		+0.57%	+47.76%

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT

Executive Committee: Anika Therapeutics, Inc.

Manager

Positions heldSince

Stephen Griffin

40 year

Chief Executive Officer	2026-01-31
President	2026-01-31

James Chase

Sales & Marketing

2018-08-05

Mira Leiwant

Chief Tech/Sci/R&D Officer	2019-10-13
General Counsel	2019-10-13

David Colleran

54 year

General Counsel	2020-03-03
Corporate Secretary	2020-03-03

Lisa Funiciello

Human Resources Officer

2022-01-31

Ian McLeod

Comptroller/Controller/Auditor	2021-06-30
Treasurer	-

Dawn J. Wilson

Chief Tech/Sci/R&D Officer

2023-08-31

Matt Hall

Investor Relations Contact

2024-08-31

Composition of the Board of Directors: Anika Therapeutics, Inc.

Director

CommitteesSince

Cheryl Blanchard

61 year

Chairman

2026-01-31

John Henneman

64 year

Governance Committee	2019-07-31
Nominating Committee	2019-07-31
Audit Committee Chair	2019-07-31
Audit Committee	2023-01-04
Finance Committee	2023-01-04
Governance Committee Chair	2024-06-17
Nominating Committee Chair	2024-06-17

Glenn Larsen

72 year

Compensation Committee	2015-02-16
Governance Committee	2015-02-16
Nominating Committee	2015-02-16

William Jellison

68 year

Audit Committee Chair
Audit Committee	2024-05-27

Sheryl Conley

65 year

Audit Committee	2021-10-27
Compensation Committee Chair	2021-10-27

Joe Capper

62 year

Compensation Committee

2024-05-27

Gary Fischetti

65 year

Compensation Committee

2023-04-12

Stephen Richard

63 year

Audit Committee Chair

2020-09-02

Stephen Griffin

40 year

Director/Board Member

2026-01-31

Latest Appointments: Anika Therapeutics, Inc.

Jan. 08	Anika Therapeutics Appoints CFO Stephen Griffin as Chief Executive Officer	MT
Jan. 08	Anika Therapeutics, Inc. Announces Executive Changes	CI
Jan. 08	Anika Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
25-04-10	Anika Therapeutics, Inc. Announces Executive Changes, Effective April 25, 2025	CI
24-05-28	Anika Therapeutics, Inc. Announces Board Changes	CI
24-05-08	Anika Therapeutics, Inc. Announces Management Changes, Effective June 3, 2024	CI
24-02-26	Anika Therapeutics, Inc. Announces Board Changes	CI

More news

Former Officers and Directors: Anika Therapeutics, Inc.

Insider

Positions held

SinceUntil

Susan Vogt

Director/Board Member	2018-10-22	2026-01-31
Independent Dir/Board Member	2018-10-22	2026-01-31

Anne Nunes

Chief Operating Officer

2021-08-31

2025-04-24

Steven Ek

Chief Tech/Sci/R&D Officer

2020-05-28

2024-10-31

Mark Namaroff

Investor Relations Contact	-	2024-08-31
Public Communications Contact	-	2024-08-31

Jeffery Thompson

Director/Board Member	2024-02-23	2024-07-08
Chairman	2020-09-02	2024-02-23
Independent Dir/Board Member	2011-01-17	2024-07-08

Michael Levitz

Director of Finance/CFO	2020-08-09	2024-05-01
Treasurer	2020-08-09	2024-05-01

Raymond J. Land

Director/Board Member	2005-12-31	2022-06-07
Independent Dir/Board Member	2005-12-31	2022-06-07

James Loerop

Corporate Officer/Principal

2019-07-07

2021-12-31

Charles Sherwood

General Counsel

2021-07-31

Joseph Bower

Director/Board Member	1992-12-31	2021-06-15
Chairman	2018-03-08	2020-09-02
Independent Dir/Board Member	1992-12-31	2021-06-15

Stephen Garbacz

Comptroller/Controller/Auditor

2019-05-05

2021-04-30

Alexei Goraltchouk

Chief Operating Officer

2018-06-10

2020-12-31

Sylvia Cheung

Comptroller/Controller/Auditor	2005-09-30	2020-08-09
Director of Finance/CFO	2013-03-31	2020-08-09
Investor Relations Contact	2005-09-30	2020-08-09
Corporate Secretary	2013-03-31	2020-03-03
Treasurer	2013-03-31	2020-08-09

Robert Richard

Chief Tech/Sci/R&D Officer

2019-03-17

2020-05-31

Joseph G. Darling

Director/Board Member	2018-03-08	2020-01-28
Chief Executive Officer	2018-03-08	2020-01-28
President	2017-07-26	2020-01-28

Edward S. Ahn

Chief Tech/Sci/R&D Officer

2014-10-29

2019-07-04

Richard Hague

Corporate Officer/Principal

2015-10-25

2019-04-04

Steven E. Wheeler

Director/Board Member	1993-01-31	2019-02-07
Independent Dir/Board Member	1993-01-31	2019-02-07

Charles Sherwood

Director/Board Member	2011-06-12	2018-03-08
Chief Executive Officer	1998-03-31	2018-03-08
President	1998-03-31	2017-07-26

Dana M. Alexander

Chief Operating Officer

2016-04-03

2018-01-11

Steven J. Chartier

Chief Tech/Sci/R&D Officer	2017-08-27	2017-12-31
General Counsel	2017-08-27	2017-12-31

Thomas Finnerty

Human Resources Officer

2017-10-29

Stephen R. Mascioli

Chief Tech/Sci/R&D Officer

2016-04-03

2017-01-22

Jean Bjerke

Sales & Marketing

2016-03-20

2016-12-31

Ellen MacKenzie

Comptroller/Controller/Auditor

2016-09-25

Christopher Ranjitkar

Investor Relations Contact

2015-05-31

2016-01-31

John C. Moran

Director/Board Member	2006-12-13	2015-12-07
Independent Dir/Board Member	2006-12-13	2015-12-07

Carol A. Barnett

Corporate Officer/Principal

2012-07-31

2014-10-28

John W. Sheets

Chief Tech/Sci/R&D Officer

2013-09-29

2014-10-27

Michael Alfieri

Comptroller/Controller/Auditor

2010-08-31

2014-06-30

Steven Cyr

Human Resources Officer

2014-03-23

Francesco J. Luppino

Chief Operating Officer	2009-05-27	2013-10-30
Corporate Officer/Principal	2006-12-31	2006-12-31
Chief Operating Officer	2014-10-29	2015-12-31

Jing-Wen Kuo

Chief Tech/Sci/R&D Officer

2011-08-22

2013-09-29

Carol Pekar

Chief Tech/Sci/R&D Officer	2013-04-30	-
General Counsel	2013-04-30	-

Kevin W. Quinlan

Director of Finance/CFO	2005-06-30	2013-03-30
Investor Relations Contact	2005-06-30	2013-03-30
Public Communications Contact	2010-07-12	2013-03-30
Corporate Secretary	2005-06-30	2013-03-30
Treasurer	2005-06-30	2013-03-30

Jill A. Wollins

Chief Tech/Sci/R&D Officer	2012-01-31	-
General Counsel	2012-01-31	-

Irina B. Kulinets

Chief Tech/Sci/R&D Officer	2007-08-31	2012-01-31
General Counsel	2007-08-31	2012-01-31

Alessandra Pavesio

Chief Tech/Sci/R&D Officer

2009-12-31

2011-11-30

Eugene A. Davidson

Director/Board Member

1993-01-31

2011-06-06

Thomas J. Chambers

Sales & Marketing

2010-07-12

Andrew Carter

Chief Tech/Sci/R&D Officer

2007-12-31

Edward Gaj

Corporate Officer/Principal	1997-12-31	2007-05-31
Corporate Officer/Principal	2012-02-29	2016-03-31

Gregory T. Fulton

Corporate Officer/Principal

2006-12-31

Harvey S. Sadow

Director/Board Member

2006-12-13

Constance H. Garrison

Corporate Officer/Principal

2006-11-12

Samuel F. McKay

Director/Board Member

2006-01-23

Randall W. Wilhoite

Chief Operating Officer	2005-12-31	2009-05-27
Corporate Officer/Principal	2009-05-27	-

James O'Neill

Comptroller/Controller/Auditor	-	2005-05-12
Director of Finance/CFO	-	2005-05-12

William J. Knight

Director of Finance/CFO

2001-12-31

2003-12-31

J. Engle

Chief Executive Officer	1995-12-31	2000-12-31
Chairman	1995-12-31	2000-12-31
President	1995-12-31	2000-12-31

Michael R. Slater

Chief Operating Officer

1997-12-31

2000-12-31

William J. Mrachek

Human Resources Officer

2000-12-31

Sean Moran

Director of Finance/CFO

1999-12-31

Carol A. Toth

Chief Tech/Sci/R&D Officer

Jim Dunfey

Comptroller/Controller/Auditor

Peter Litman

Corporate Officer/Principal

Ellen Snow

Comptroller/Controller/Auditor

Scott Bruder

Chief Tech/Sci/R&D Officer

Julie N. Broderick

General Counsel

Hyun D. Kim

Corporate Officer/Principal

Laura Mondano

General Counsel

Edward Ross

Corporate Officer/Principal

Elizabeth Chen

Sales & Marketing

R. Alan B. Ezekowitz

Director/Board Member

2009-08-19

Joshua Reinhart

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	12
Female	4

Of which Executive Committee

Male	5
Female	3

Of which Directors

Male	8
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.

Employees

235

Sector

Medical Equipment, Supplies & Distribution

More about the company